These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19201511)

  • 1. [Hematological disorders and hypereosinophilias].
    Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
    Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilia: secondary, clonal and idiopathic.
    Tefferi A; Patnaik MM; Pardanani A
    Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophilia in Hematologic Disorders.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
    Bain BJ
    Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
    Roufosse F; Goldman M; Cogan E
    Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
    Tefferi A; Pardanani A
    Int J Hematol; 2004 Jun; 79(5):441-7. PubMed ID: 15239393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
    Kjeldsen E
    Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
    Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A
    Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.